Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC
MetadataShow full item record
<jats:p>Polyinosinic:polycytidylic acid (poly IC), a double-stranded RNA, is an effective adjuvant in vivo. IFN-λs (also termed IL-28/29) are potent immunomodulatory and antiviral cytokines. We demonstrate that poly IC injection in vivo induces large amounts of IFN-λ, which depended on hematopoietic cells and the presence of TLR3 (Toll-like receptor 3), IRF3 (IFN regulatory factor 3), IRF7, IFN-I receptor, Fms-related tyrosine kinase 3 ligand (FL), and IRF8 but not on MyD88 (myeloid differentiation factor 88), Rig-like helicases, or lymphocytes. Upon poly IC injection in vivo, the IFN-λ production by splenocytes segregated with cells phenotypically resembling CD8α+ conventional dendritic cells (DCs [cDCs]). In vitro experiments revealed that CD8α+ cDCs were the major producers of IFN-λ in response to poly IC, whereas both CD8α+ cDCs and plasmacytoid DCs produced large amounts of IFN-λ in response to HSV-1 or parapoxvirus. The nature of the stimulus and the cytokine milieu determined whether CD8α+ cDCs produced IFN-λ or IL-12p70. Human DCs expressing BDCA3 (CD141), which is considered to be the human counterpart of murine CD8α+ DCs, also produced large amounts of IFN-λ upon poly IC stimulation. Thus, IFN-λ production in response to poly IC is a novel function of mouse CD8α+ cDCs and their human equivalents.</jats:p>
Place of Publication
Recommended, similar items
The following license files are associated with this item:
Showing items related by title, author, creator and subject.
Altered Toll-like Receptor 2-mediated Endotoxin Tolerance Is Related to Diminished Interferon β Production Zaric, Svetislav; Coulter, WA; Shelburne, CE; Fulton, CR; Zaric, MS; Scott, A; Lappin, MJ; Fitzgerald, DC; Irwin, CR; Taggart, CC (Elsevier BVUnited States, 2011-08)Induction of endotoxin tolerance leads to a reduced inflammatory response after repeated challenge by LPS and is important for resolution of inflammation and prevention of tissue damage. Enterobacterial LPS is recognized ...
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study Ziemssen, T; Bass, A; Berkovich, R; Comi, G; Eichau, S; Hobart, J; Hunter, SF; LaGanke, C; Limmroth, V; Pelletier, D; Pozzilli, C; Schippling, S; Sousa, L; Traboulsee, A; Uitdehaag, BMJ; Van Wijmeersch, B; Choudhry, Z; Daizadeh, N; Singer, BA (Springer VerlagNew Zealand, 2020-07-24)BACKGROUND: Alemtuzumab efficacy versus subcutaneous interferon-β-1a (SC IFNB-1a) was demonstrated over 2 years in patients with relapsing-remitting multiple sclerosis, with continued efficacy over 7 additional years. ...
Impact of direct‐acting antiviral agents on liver function in patients with chronic hepatitis C virus infection Johnson, PJ; Berhane, S; Walker, AJ; Gordon, FH; Ryder, SD; McPherson, S; Sreedharan, A; Ustianowski, AA; Agarwal, K; Mutimer, D; Kumada, T; Toyoda, H; Irving, WL; Agarwal, K; Aldersley, M; Ala, A; Aspinall, R; Barnes, E; Brown, A; Corless, L; Cramp, Matthew; Forton, D; Foster, G; Foxton, M; Gelson, W; Gorard, D; Gordon, F; Khakoo, S; Lawson, A; McPherson, S; Moreea, S; Mutimer, D; Prince, M; Richardson, P; Rosenberg, W; Ryder, S; Sreedharan, A; Stone, B; Ustianowski, A; Verma, S; Wiselka, M (WileyEngland, 2021-01)Whilst the benefit of direct-acting antiviral agents (DAAs) in achieving sustained virological response (SVR) is now well-accepted, their impact on liver function, particularly in relation to achievement of SVR, has not ...